Could This COVID-19 Drug Developer's Stock Make You Filthy Rich?
It's safe to say that the bulk of healthcare investors' attention has settled on players in the coronavirus vaccine race. But biotech and pharmaceutical companies are also working to develop drugs that can treat patients already diagnosed with COVID-19, the virus that has led to economic shutdowns worldwide and over 190,000 deaths in the U.S. alone. Over 1,900 clinical studies are currently recruiting trial participants or are in active pre-trial stages, according to the National Institutes of Health (NIH). That count includes vaccine trials, but also potential treatments ranging from hydroxychloroquine, to plasma-based therapies, and even traditional Chinese medicines.
It's impossible to guess which -- if any -- of the studied treatments will be successful until they earn regulatory approvals. But at this stage, one particular company's efforts have already caught my eye: Regeneron Pharmaceuticals (NASDAQ: REGN) is developing its investigational antibody therapy to treat and prevent COVID-19. That's two markets, and two major opportunities. If the treatment is safe and effective for both types of use, Regeneron could hit the jackpot. And if you buy the stock, you might too. Let's take a closer look at this biotech company's program.
Image source: Getty Images
Source Fool.com
